<DOC>
	<DOCNO>NCT02106897</DOCNO>
	<brief_summary>The primary objective Parts 1 2 evaluate safety tolerability either single-ascending intravenous ( IV ) dose single subcutaneous ( SC ) dose BIIB059 healthy volunteer ( HV ) , single IV dose participant Systemic Lupus Erythematosus ( SLE ) . The primary objective Part 3 evaluate safety tolerability multiple SC dose BIIB059 healthy volunteer participant SLE . Secondary objectives Parts 1 2 follow : To estimate PK parameter single-ascending IV dose BIIB059 healthy volunteer single IV dose BIIB059 participant SLE ; To estimate PK parameter bioavailability ( F ) single SC dose BIIB059 healthy volunteer ; To evaluate immunogenicity BIIB059 administer healthy volunteer participant SLE . Secondary objective Part 3 follow : To estimate PK parameter multiple SC dose BIIB059 healthy volunteer participant SLE ; To evaluate immunogenicity BIIB059 administer SC healthy volunteer participant SLE .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , Pharmacokinetics Single Doses Multiple Doses BIIB059 Healthy Volunteers Participants With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Part 1 ( single ascend dose healthy volunteer ) close enrollment .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Part 1 : Key Inclusion Criteria For Healthy Volunteers : Be good health determine Investigator , base medical history , physical examination , 12lead ECG . Body mass index ( BMI ) 18 30 kg/m2 body weight ≥45 kg . Part 1 : Key Exclusion Criteria For Healthy Volunteers : History positive test result screen follow : human immunodeficiency virus ( HIV ) , hepatitis C virus antibody ( HCV Ab ) , hepatitis B virus ( define positive hepatitis B surface antigen [ HBsAg ] hepatitis B core antibody [ HBcAb ] ) . History chronic , recurrent , recent serious infection ( e.g. , pneumonia , septicemia ) determine Investigator within 3 month prior screen randomization . History severe allergic anaphylactic reaction history allergic reaction likely exacerbate component study drug . History clinically significant cardiovascular , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator . Any live attenuate immunization/vaccination within 1 month prior randomization plan occur study period . Blood donation ( 1 unit ) within 1 month prior randomization . Vigorous exercise ( e.g. , jogging , swim lap , heavy gardening , hike uphill , etc . ) within 48 hour prior Day 1 Part II : Key Inclusion Criteria SLE Participants : Definite SLE least 6 month duration antidsDNA antibody , prior screen . Presence active lupus skin disease include acute , sub acute , and/or chronic cutaneous lupus ( e.g. , discoid ) time screen randomization . BMI 18 &lt; 40 kg/m2 body weight ≥45 kg . Part II : Key Exclusion Criteria SLE Participants : Active neuropsychiatric SLE include limited following : seizure , new worsen impaired level consciousness , psychosis , delirium confusional state , aseptic meningitis , ascend transverse myelitis , chorea , cerebellar ataxia , mononeuritis multiplex , demyelinate syndrome . History chronic , recurrent , recent serious infection ( e.g. , pneumonia , septicemia ) determine Investigator within 3 month prior screen randomization . Symptoms bacterial viral infection ( include upper respiratory tract infection ) within 28 day prior randomization . History severe allergic anaphylactic reaction history allergic reaction likely exacerbate component study drug . Evidence skin condition lupus skin disease ( e.g. , eczema ) screening time randomization would interfere evaluation effect study treatment lupus skin disease . Treatment oral prednisone &gt; 15 mg daily ( equivalent ) . Any prednisone regimen must stable least 28 day randomization expect remain stable duration study . Treatment antibiotic within 14 day prior randomization . Part IIIa : Key Inclusion Criteria Healthy Volunteers : Must good health determine Investigator , base medical history , physical examination , 12lead ECG . Must body mass index ( BMI ) 18 30 kg/m2 body weight ≥45 kg . Part IIIa : Key Exclusion Criteria Healthy Volunteers : History chronic , recurrent , recent serious infection ( e.g. , pneumonia , septicemia ) determine Investigator within 3 month prior screen randomization History severe allergic anaphylactic reaction history allergic reaction likely exacerbate component study treatment . Treatment antibiotic within 14 day prior randomization . Part IIIb : Key Inclusion Criteria SLE Participants : Definite SLE least 6 month duration prior screen Presence active lupus skin disease include acute , subacute , and/or chronic cutaneous lupus ( e.g. , discoid ) , and/or hypocomplementemia , and/or positive antidsDNA antibody time screen . Must BMI 18 &lt; 40 kg/m2 body weight ≥45 kg . Part IIIb : Key Exclusion Criteria SLE Participants : Active neuropsychiatric SLE include limited following : seizure , new worsen impaired level consciousness , psychosis , delirium confusional state , aseptic meningitis , ascend transverse myelitis , chorea , cerebellar ataxia , mononeuritis multiplex , demyelinate syndrome . History chronic , recurrent , recent serious infection ( e.g. , pneumonia , septicemia ) determine Investigator within 3 month prior screen randomization . History severe allergic anaphylactic reaction history allergic reaction likely exacerbate component study drug . Treatment antibiotic within 14 day prior randomization . NOTE : Other protocoldefined inclusion/exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>